Acadia Pharmaceuticals

News

EC greenlights Acadia’s DAYBU for Rett Syndrome in Europe

Acadia Pharmaceuticals has secured EC approval for DAYBU (trofinetide) for the neurobehavioural symptoms of Rett syndrome in the EU.

News

Acadia, Harmony record late-stage rare disease failures

Biotechs Acadia Pharma and Harmony Biosciences both suffered setbacks in phase 3 trials of drugs for rare diseases, in one case ending the programme.

Patients

Jonah Comstock interview with Catherine Owen Adams at JP Morgan week 2025

JP Morgan Week 2025 – Catherine Owen Adams

Explore the insightful video interview with Catherine Owen Adams during JP Morgan Week 2025.

News

Steve Davis, president and chief executive of Acadia Pharma

Acadia pulls trials of pimavanserin after schizophrenia fail

Acadia Pharma’s plan to develop pimavanserin as a treatment for additional indications is in disarray after the drug failed a phase 3 trial in schizophrenia.

News

FDA panel turns down Acadia's Nuplazid for Alzheimer's psych...

Acadia Pharma's attempts to extend the indications of its Nuplazid drug in the US to include Alzheimer's disease-related psychosis have suffered another major setback.

News

Acadia closer to bringing first Rett syndrome drug to market

Acadia Pharma's trofinetide has hit its efficacy targets in a phase 3 trial involving girls with the devastating neurological disorder Rett syndrome, although safety has dampened enthusiasm

EC greenlights Acadia’s DAYBU for Rett Syndrome in Europe

Acadia, Harmony record late-stage rare disease failures

JP Morgan Week 2025 – Catherine Owen Adams

Acadia pulls trials of pimavanserin after schizophrenia fail

FDA panel turns down Acadia's Nuplazid for Alzheimer's psych...

Acadia closer to bringing first Rett syndrome drug to market

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

Acadia Pharmaceuticals

Editor's Picks